BEUDAMED
    10 results · 7ms · Sources: EU EUDAMED, US FDA

    Get notified when this changes

    We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.
    Filters FDA Classification × Classification: FDA Class 2 × Clear all

    Software Device To Aid In The Prediction Or Diagnosis Of Sepsis

    FDA classification
    FDA Class 2 ·Software Device To Aid In The Prediction Or Diagnosis Of Sepsis

    Microfilter, Blood Transfusion

    FDA classification
    FDA Class 2 ·Microfilter, Blood Transfusion

    Complement C1q, Antigen, Antiserum, Control

    FDA classification
    FDA Class 2 ·Complement C1q, Antigen, Antiserum, Control

    Sars-Cov-2 Serology Test

    FDA classification
    FDA Class 2 ·Sars-Cov-2 Serology Test

    Non-Sars Coronavirus Multiplex Nucleic Acid Assay

    FDA classification
    FDA Class 2 ·Non-Sars Coronavirus Multiplex Nucleic Acid Assay

    Respiratory Specimen Nucleic Acid Sars-Cov-2 Test

    FDA classification
    FDA Class 2 ·Respiratory Specimen Nucleic Acid Sars-Cov-2 Test

    Over-The-Counter Molecular Test To Detect Sars-Cov-2 From Clinical Specimens

    FDA classification
    FDA Class 2 ·Over-The-Counter Molecular Test To Detect Sars-Cov-2 From Clinical Specimens

    Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents

    FDA classification
    FDA Class 2 ·Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents

    Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings

    FDA classification
    FDA Class 2 ·Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings

    Simple Point-Of-Care Device To Detect Sar-Cov-2 Nucleic Acid Targets From Clinical Specimens In Near-Patient Settings

    FDA classification
    FDA Class 2 ·Simple Point-Of-Care Device To Detect Sar-Cov-2 Nucleic Acid Targets From Clinical Specimens In Near-Patient Settings